Abstract: Shown are a device, system and method that improve the diabetes care of a patient that has undergone gastric surgery. The device provides continuously or intermediate monitoring at various intervals before and after meals of several sensors to perceive, among other things, the blood glucose level, EKG/heart rate and volume of meals a patient has consumed. Readings are sent to a control unit that receives input from at least one of: a meal sensor, glucose monitor, and EKG sensor to control a drug delivery unit that doses a prescribed agent at a specific quantity and time based on the readings to provide proper diabetes care for the patient. Components of the system such as the meal sensor glucose monitor, EKG sensor, control unit and drug delivery device may be implanted subcutaneously in the patient or outside the patient and may communicate with each other either wirelessly or may be directly wired together.

Abstract: Disclosed are compositions and methods for increasing diabetes resolution in a diabetic patient having undergone gastric restrictive surgery, entailing use of active agent that produces an incretin-like effect in the patient.

Abstract: Disclosed are compositions and methods for increasing diabetes resolution in a diabetic patient having undergone gastric restrictive surgery, entailing use of active agent that produces an incretin-like effect in the patient.

Abstract: Disclosed are compositions and methods for increasing diabetes resolution in a diabetic patient having undergone gastric restrictive surgery, entailing use of active agent that produces an incretin-like effect in the patient.

Abstract: Disclosed are compositions and methods for increasing diabetes resolution in a diabetic patient having undergone gastric restrictive surgery, entailing use of active agent that produces an incretin-like effect in the patient.

Abstract: Methods of treating malnutrition associated with chronic lung diseases comprising the administration of metabolically active peptides in an amount sufficient to increase circulating somatomedin C levels more than 0.8 U/ml plasma above the patient's baseline SmC level, along with nutritional supplementation providing a daily caloric intake of between 100% and 200% of the patient's baseline resting energy expenditure; and formulations utilized therein.